Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04692077 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT04692077 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 9 participants.
The verdict
NCT04692077, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study will establish the minimum safety, tolerability and acceptability data needed to support the use of cabotegravir long-acting injection (CAB LA) in an adolescent population, potentially transforming the field of HIV prevention for young people.
Interventions
- DRUG CAB LA
- DRUG Cabotegravir (CAB) tablet
- DRUG Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-02-19 |
| Est. Completion | 2023-07-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04692077
The ClinicalTrials.gov registry entry for NCT04692077 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CAB LA is the first listed.
NCT04692077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04692077 about?
NCT04692077 is a clinical study titled "Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males". This study will establish the minimum safety, tolerability and acceptability data needed to support the use of cabotegravir long-acting injection (CAB LA) in an adolescent population, potentially transforming the field of HIV prevention for young people.
What is the current status of trial NCT04692077?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-02-19. Estimated completion is 2023-07-07.
What interventions are being tested in trial NCT04692077?
The interventions under investigation include: CAB LA (DRUG), Cabotegravir (CAB) tablet (DRUG), Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet (DRUG).
Who is sponsoring clinical trial NCT04692077?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.